An interventional study of Paclitaxel plus carboplatin and radiotherapy in Esophageal Squamous Cell Carcinoma, Chemoradiotherapy and Survival, sponsored by Fudan University. Recruiting at 3 sites in China. Open to participants aged 76 Years and older. Per ClinicalTrials.gov, last updated 2021-11-02.
Sponsored by Fudan University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing paclitaxel in Esophageal Squamous Cell Carcinoma — 10 open to participants now, 14 under way, 3 of them phase 3. Paclitaxel · Esophageal Squamous Cell Carcinoma.
Among the 43 studies testing paclitaxel in Esophageal Squamous Cell Carcinoma, this one is the 6th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2020, is the only one with no phase, reaches primary completion later than 4 of the 13 other live ones, and was the 32nd registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →10 of the 43 studies testing paclitaxel in Esophageal Squamous Cell Carcinoma are open now, in 6 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Fujian Medical University Union Hospital · Sites in China
Ages 18–75
Sichuan University · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 76 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 34 · Phase 3 6
First in 1995; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 56 across the 39 interventional studies. Of the 20 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 43 have an industry lead sponsor. The 10 most frequent:
Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
37 studies in Esophageal Squamous Cell Carcinoma by Fudan University: 12 open now, 15 under way, 2 of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 37 studies in Esophageal Squamous Cell Carcinoma by Fudan University, this one is the 6th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 with no phase, reaches primary completion later than 3 of the 14 other live ones, and was the 21st registered.
Fudan University’s Esophageal Squamous Cell Carcinoma studies by the year they started, since 2008.
4 of the studies testing paclitaxel in Esophageal Squamous Cell Carcinoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04460352Phase 3Karolinska University HospitalChemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer | 2026-12-31 |
| NCT06601309Fujian Medical University Union HospitalBiomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC | 2027-03-31 |
| NCT07751055Sun Yat-sen UniversityNeoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer | 2027-04-01 |
| NCT07317609Shanghai Zhongshan HospitalNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing paclitaxel in Esophageal Squamous Cell Carcinoma, from their registry updates:
Among Fudan University’s 37 in Esophageal Squamous Cell Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
So far, there is no specific clinical guideline for elderly patients (>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx) or the chemoradiotherapy group (50.4Gy/28Fx;Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.
Up to now, definitive radiotherapy was major treatment plan for elderly ESCC patients. However, whether elective elderly patients can obtain survival benefits through chemoradiotherapy is not clear. Thus we design the clinical trail to answer the question.
Three hundred and twenty elderly patients with ESCC would be recruited. There are two stratification factors including 80 years old and lymph node metastasis. The patients in the chemoradiotherapy group were treated with paclitaxel (45mg/m2) and carboplatin (AUC=2) one cycle per week for five cycles.The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival. The life quality questionnaire included QlQ-C30 and OES-18.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50.4Gy/28Fx; Paclitaxel plus carboplatin
Drug: Paclitaxel plus carboplatin · Radiation: radiotherapy
61.2Gy/34Fx
Radiation: radiotherapy
Drug pages: PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Paclitaxel (45mg/m2) plus carboplatin (AUC=2); five cycles; qw
Different radiotherapy dose in different groups.
overall survival difference of definitive radiotherapy and chemoradiotherapy groups
The time between the start of the study treatment (Day 1) and death from any cause or last follow-up for patients alive at the end of the study.
Time frame: 3-year
difference of quality of life between different groups
Assess the quality of life through life quality questionnaire.
Time frame: the period of treatment within 7 weeks and follow up time with an average of 3months
radiation side effects
Record the radiation side effects including acute and late side effects.
Time frame: acute side effects within 3 months, late side effects for 3 months later
cancer specific survival
The time between the start of the study treatment (Day 1) and death from tumor or last follow-up for patients alive at the end of the study.
Time frame: 3-year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2020 (actual). Primary completion is estimated for Dec 2024, 59 months after the start.
Of 37 interventional studies with no phase under Esophageal Squamous Cell Carcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25. This study's planned 59 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paclitaxel · Carboplatin
Esophageal Squamous Cell Carcinoma →